| 0.8544 -0.038 (-4.24%) | 10-14 10:55 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.53 |
1-year : | 1.89 |
| Resists | First : | 1.31 |
Second : | 1.62 |
| Pivot price | 1 |
|||
| Supports | First : | 0.82 |
Second : | 0.68 |
| MAs | MA(5) : | 0.91 |
MA(20) : | 1.05 |
| MA(100) : | 1.14  |
MA(250) : | 1 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 11.1 |
D(3) : | 15.2 |
| RSI | RSI(14): 29.6 |
|||
| 52-week | High : | 1.65 | Low : | 0.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BFRI ] has closed above bottom band by 14.2%. Bollinger Bands are 26.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.94 - 0.95 | 0.95 - 0.95 |
| Low: | 0.86 - 0.86 | 0.86 - 0.87 |
| Close: | 0.88 - 0.89 | 0.89 - 0.9 |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Thu, 08 Oct 2026
Red-light treatment cleared every treated precancerous spot in 45.6% of patients. - Stock Titan
Thu, 08 Oct 2026
Biofrontera Submits Supplemental New Drug Application to - GlobeNewswire
Sat, 03 Oct 2026
Biofrontera Inc. (NASDAQ:BFRI): Are Analysts Optimistic? - Simply Wall Street
Thu, 13 Aug 2026
Biofrontera Inc (BFRI) (Q2 2026) Earnings Call Highlights: Strong Ameluz Growth Drives Revenue ... - Yahoo Finance
Thu, 13 Aug 2026
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth - GlobeNewswire
Thu, 13 Aug 2026
Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 15 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 11.9 (%) |
| Held by Institutions | 20.7 (%) |
| Shares Short | 147 (K) |
| Shares Short P.Month | 255 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.41 |
| Profit Margin | -13.8 % |
| Operating Margin | -4.4 % |
| Return on Assets (ttm) | -17.5 % |
| Return on Equity (ttm) | -988.4 % |
| Qtrly Rev. Growth | 32.9 % |
| Gross Profit (p.s.) | 2.46 |
| Sales Per Share | 3.1 |
| EBITDA (p.s.) | -0.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -1.98 |
| PEG Ratio | 0 |
| Price to Book value | 2.02 |
| Price to Sales | 0.27 |
| Price to Cash Flow | -1.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|